STAAR Surgical
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for visi...
Latest News
12 days ago · marketbeat.com
What STAAR Surgical (STAA) Said on Its Q3 Earnings CallSTAAR Surgical NASDAQ: STAA reported lower third-quarter sales and profit on a reported basis, but said revenue rose 21% after excluding a prior-year deferred sales item in China. The implantable lens maker also said demand for higher-priced products in China exceeded its ability to supply them during the quarter.
12 days ago · seekingalpha.com
STAAR Surgical Company (STAA) Q3 2026 Earnings Call TranscriptSTAAR Surgical Company (STAA) Q3 2026 Earnings Call Transcript
12 days ago · zacks.com
Staar Surgical (STAA) Surpasses Q3 Earnings and Revenue EstimatesStaar Surgical (STAA) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.46 per share a year ago.
19 days ago · businesswire.com
STAAR Surgical Appoints Pascal Aeschlimann as Vice President of Asia PacificLAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the appointment of Pascal Aeschlimann as Vice President of Asia Pacific, effective November 2, 2026. Mr. Aeschlimann, who led STAAR's commercial expansion across Asia and the Middle East from 2002 to 2010, returns after more than a decade building and leading.
20 days ago · zacks.com
Earnings Preview: Staar Surgical (STAA) Q3 Earnings Expected to DeclineStaar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
1 month ago · gurufocus.com
STAAR Surgical Names Andrew Pilon as Vice President of Business DevelopmentSTAAR Surgical Company (âSTAARâ or the âCompanyâ) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer Lenses
2 months ago · fool.com
Why Staar Surgical Zoomed Almost 8% Higher on TuesdayThat pundit now believes it's a buy. He cited positive sales momentum, especially in a key market overseas.
2 months ago · benzinga.com
This Staar Surgical Analyst Turns Bullish; Here Are Top 5 Upgrades For TuesdayTop Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
2 months ago · fool.com
Why Staar Surgical Stock Soared TodayIt anticipates this will run for one year. The company's recent fundamentals have been rather impressive.
2 months ago · businesswire.com
STAAR Surgical Names Former CEO David Bailey as Chief Commercial OfficerLAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the appointment of David Bailey as Chief Commercial Officer. Mr. Bailey will join STAAR's executive committee and report to Warren Foust, President and Chief Executive Officer. "David Bailey doesn't just know STAAR, he helped change the trajectory of the entir.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove STAA